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Abstract
Large-scale sequencing of human cancer genomes and mouse transposon-induced tumors has identified a vast number of
genes mutated in different cancers. One of the outstanding challenges in this field is to determine which genes, when
mutated, contribute to cellular transformation and tumor progression. To identify new and conserved genes that drive
tumorigenesis we have developed a novel cancer model in a distantly related vertebrate species, the zebrafish, Danio rerio.
The Sleeping Beauty (SB) T2/Onc transposon system was adapted for somatic mutagenesis in zebrafish. The carp ß-actin
promoter was cloned into T2/Onc to create T2/OncZ. Two transgenic zebrafish lines that contain large concatemers of T2/
OncZ were isolated by injection of linear DNA into the zebrafish embryo. The T2/OncZ transposons were mobilized
throughout the zebrafish genome from the transgene array by injecting SB11 transposase RNA at the 1-cell stage.
Alternatively, the T2/OncZ zebrafish were crossed to a transgenic line that constitutively expresses SB11 transposase. T2/
OncZ transposon integration sites were cloned by ligation-mediated PCR and sequenced on a Genome Analyzer II. Between
700–6800 unique integration events in individual fish were mapped to the zebrafish genome. The data show that
introduction of transposase by transgene expression or RNA injection results in an even distribution of transposon re-
integration events across the zebrafish genome. SB11 mRNA injection resulted in neoplasms in 10% of adult fish at ,10
months of age. T2/OncZ-induced zebrafish tumors contain many mutated genes in common with human and mouse cancer
genes. These analyses validate our mutagenesis approach and provide additional support for the involvement of these
genes in human cancers. The zebrafish T2/OncZ cancer model will be useful for identifying novel and conserved genetic
drivers of human cancers.
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Introduction
In sporadic human cancers the initiating event is proposed to be
an oncogenic mutation that activates cell growth pathways and
leads to cellular transformation. Subsequent cancer progression
and metastasis are associated with genomic instability and
defective DNA repair, leading to the accumulation of large
numbers of somatic mutations [1,2,3]. Large scale sequencing of
human cancer genomes has revealed a vast array of somatic
mutations in breast, colon, lung, glioma, ovarian, pancreatic, and
prostate cancers [4,5,6,7,8,9]. A subset of these somatic mutations,
termed drivers, are thought to provide a selective growth
advantage in cancer cells, promoting cellular transformation and
progression to metastasis. The majority of mutations, termed
passengers, are carried along as the cancer cell population
expands. Distinguishing driver and passenger mutations within
the human cancer genome has been a major hurdle in identifying
causal mutations in different cancers. A major goal in the field is to
correlate cancer genotype with clinically relevant phenotypes in
order to develop effective therapies for specific cancers.
One approach to identify new cancer genes and associated
causal mutations is to compare the mutation profiles between
human cancers and animal cancer models. A successful strategy
for cancer gene identification has been developed in mice using the
DNA transposon system Sleeping Beauty (SB) for insertional somatic
mutagenesis [10,11,12,13]. The SB system was originally recon-
stituted from inactive elements present in the genomes of salmonid
species [14]. Because SB shows minimal site specificity aside from
the presence of a TA dinucleotide at the integration site [15], it is
an effective tool for random mutagenesis. In the mouse somatic
mutagenesis cancer models the mutagenic SB transposon, T2/Onc,
was designed to create loss- and gain-of-function mutations similar
to those that drive tumorigenesis in sporadic human cancers. The
system was shown to induce primarily hematopoietic tumors in
adult mice and solid tumors at a lower frequency [10,11]. Recent
modifications to the system using an alternative T2/Onc
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been shown to produce a wide range of epithelial-derived
carcinomas [16] and tissue-specific cancers including hepatocel-
lular carcinoma [17] and gastrointestinal neoplasms [18]. Analyses
of common integration sites across multiple tumor samples have
identified putative cancer genes associated with the various types
of neoplasms in the mouse T2/Onc-induced cancers. Comparative
studies with the genes identified in mice and human cancer
genomes have revealed a set of mutated genes in common with
human cancers [17,18,19]. These studies underscore the impor-
tance of model systems for validating known cancer genes and
identifying novel genes and signaling pathways mutated in
sporadic human carcinogenesis.
The development of cancer models in the more distantly related
vertebrate species, zebrafish, has demonstrated the conservation of
gene pathways underlying cancer [20,21,22,23]. Zebrafish models
of human cancers have been created in which tissue-specific over-
expression of oncogenes causes soft tissue cancers and solid tumors
[24,25,26,27,28,29]. Loss of function tumor suppressor lines have
been identified that result in solid tumors at varying frequencies
[30,31,32]. Application of the mouse SB-induced mutagenesis
strategy [10,11] would provide a new method to genetically screen
for novel cancer genes in zebrafish. Given the high fecundity and
inexpensive cost of zebrafish compared to mammalian model
systems, large-scale screens approaching saturation mutagenesis of
the cancer genome are a possibility in fish. Here we report the
adaptation of the SB T2/Onc system for somatic mutagenesis in
zebrafish. The T2/Onc transposon was modified by addition of the
carp ß-actin promoter[33], which is widely expressed in zebrafish
tissues. We isolated stable transgenic lines that have large copy
number concatemers of T2/OncZ transposons. Introduction of a
transient or constitutive source of SB11 transposase activates T2/
OncZ excision from the concatemer and genome-wide re-
integration in somatic tissues. Somatic mutagenesis leads to solid
tumor induction in ,10% of adult fish. Comparative analysis of
the T2/OncZ integration sites from the zebrafish tumor samples
reveals a many genes in common with human and mouse cancer
genes. This study demonstrates the capability of the Sleeping Beauty
T2/OncZ system for genome-wide insertional mutagenesis in
somatic tissues in zebrafish and its potential for identifying novel
cancer genes.
Results
A modified T2/Onc transposon system for somatic
mutagenesis in zebrafish
The T2/Onc transposon used in previous mouse models
contains elements to terminate transcription and promote over-
expression after the transposon inserts in or near a gene [10,11].
The MSCV 59 LTR promoter in T2/Onc drives high-level
expression in hematapoietic tissues in mouse. However, it was
unknown how well this promoter would be expressed when
integrated into the zebrafish genome. In addition, we wanted to
build a T2/Onc transposon that contains a promoter that is widely
expressed in various tissues and cell types. We altered T2/Onc by
addition of the carp ß-actin promoter [33], which has been used
extensively to drive constitutive and ubiquitous expression in fish
species [34]. The promoter is defined by 2.5 Kb of upstream
sequence, the first exon which is non-coding, and the first intron
which contains elements necessary for high level expression from
the promoter [35]. The splice acceptor sequences (SA) at the 39
end of intron 1 were removed to force splicing out of the
transposon and into downstream exons after insertion into a gene.
The modified ß-actin promoter was cloned into T2/Onc behind
the MSCV 59 LTR to create T2/OncZ (Fig. 1 A).
To isolate transgenic fish carrying large arrays of T2/OncZ we
used a standard transgenesis method of injecting linear DNA
fragments into the 1-cell zebrafish embryo. A 4.9 Kb linear
fragment containing T2/OncZ was released from the plasmid
vector and mixed with a linear fragment containing a widely
expressed ß-actin:RFP reporter cassette [36] before injection (Fig. 1
A). After injection into the 1-cell embryo the T2/OncZ and RFP
reporter fragments ligate via the non-homologous end-joining
pathway to form a concatemer that inserts randomly into the
genome. We used the RFP reporter to screen for transgenic
progeny and to follow the concatemer through subsequent
generations. Out of 54 founder F0 adults screened by outcrossing
with wild type zebrafish, we identified 7 F0s that produced from 3–
10% RFP+ embryos in the F1 generation (Fig 1 B). The 7
independent F1 lines were raised and outcrossed to create an F2
generation. The transgenic embryos are easily distinguished by
ubiquitous RFP expression, and adults appear red due to high
levels of RFP expression from multiple ß-actin:RFP reporter
cassettes in the concatemer (Fig. 1 B).
The copy number of the T2/OncZ transposon in the concatemer
lines was determined by genomic Southern blot analysis of DNA
isolated from F2 adults (Fig. 1 C). Plasmid DNA containing the
T2/OncZ transposon was loaded in amounts corresponding to 1,
10 or 100 copies/genome and used as a reference to estimate the
transposon copy number in each line by densitometry. The
number of transposons in the concatemers ranged from ,5t o
.100 copies (Fig. 1 C). Additional Southern blot analyses
consistently indicated that the number of transposons in the
Tg(T2/OncZ,ß -actin:RFP)
is6 line 6 far exceeded 100. To clarify this
issue, we again examined the estimated copy number of
transposons in the line 7 and line 6 concatemers in the F3
generation (Fig. 1 D). The results indicate that line Tg(T2/OncZ,ß -
actin:RFP)
is7 contains 70–100 transposons, while Tg(T2/OncZ,ß -
actin:RFP)
is6 contains .500 transposons. While our analysis
provides only an estimate of the actual number of T2/OncZ
transposons in the concatemers, the important point, as demon-
strated below, is that both concatemer lines have a large number
of transposons that are capable of robust transposition and
reintegration in somatic tissues. We have maintained lines Tg(T2/
OncZ,ß -actin:RFP)
is7 and Tg(T2/OncZ,ß -actin:RFP)
is6 and observed
that the concatemers appear stable, behave like a single copy locus,
and show a Mendelian pattern of inheritance through 5
generations to date (data not shown).
To isolate a transgenic line that constitutively expresses SB11
transposase [37], a transgenesis vector was assembled inside the
miniTol2 transposon [38] for Tol2 transposase-mediated integra-
tion into the genome. The carp ß-actin promoter [33] was used to
express SB11 cDNA from within the transposon (Fig. 2 A). For a
marker of transgenesis, a heart-specific reporter cassette contain-
ing the cardiac myosin light chain 2 (cmlc2) promoter [39,40]
driving EGFP was cloned into the miniTol2 vector 39 to the SB11
expression cassette. To isolate transgenic lines carrying single
copies of the ß-actin:SB11, cmlc2:EGFP transposon, the vector and
Tol2 mRNA were co-injected into 1-cell embryos. Founder F0
embryos were raised to adulthood and screened for transgenic
progeny by outcrossing with wild type zebrafish and scoring EGFP
expression in the heart. Nine independent lines were isolated that
carry a single Tol2,ß-actin:SB11, cmlc2:GFP. transgene insertion
and two were maintained (Table 1). Expression of the SB11
transposase was confirmed in line Tg(Tol2,ß-actin:SB11,
cmlc2:GFP.)
is8 by western blotting of 5-hour post fertilization
(hpf) embryos (Fig. 2 B).
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PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18826Figure 1. Isolation of transgenic T2/OncZ concatemer lines. (A) T2/OncZ transposon vector and RFP reporter used to isolate concatemers. IRL
and IRR, left and right transposon inverted repeats; SA, splice acceptor from intron 1 of ß-actin gene; MSCV 59 LTR, murine stem cell virus 59 long
terminal repeat; ß-actin,ß -actin promoter minus splice acceptor at 39 end; SD, splice donor; En2-SA, splice acceptor from mouse engrailed 2 gene; pA,
SV40 polyadenylation sequence; AFP, ocean pout antifreeze protein 39 UTR; black bar represents probe used on genomic Southerns shown in panel C.
Grey box represents probe used on genomic Southerns shown in panel D. Linear DNA fragments of T2/OncZ and the ß-actin:RFP reporter gene were
mixed and co-injected into 1-cell zebrafish embryos. (B) Adult F0 founders were outcrossed to wild type and transgenic F1 embryos identified by
ubiquitious RFP fluorescence. (C) Genomic Southern blots to estimate transposon copy number in Tg(T2/OncZ,ß -actin:RFP) concatemer lines 1–7.
DNA was isolated from F2 generation heterozygous adults. (D) Genomic Southern blot of DNA isolated from F3 generation heterozygous Tg(T2/OncZ,
ß-actin:RFP)
is7 and Tg(T2/OncZ,ß -actin:RFP)
is6 adults. Plasmid pT2/OncZ was loaded as reference in copy # control lanes.
doi:10.1371/journal.pone.0018826.g001
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ability of the T2/OncZ transposon to excise from the concatemer,
we used a PCR-based assay as described previously [10]. We used
two methods for introducing SB11 transposase into the Tg(T2/
OncZ,ß -actin:RFP) transgenic fish. In the first method, in vitro
transcribed SB11 mRNA was injected into 1-cell embryos from
Tg(T2/OncZ,ß -actin:RFP) fish (Fig. 3 A). In the second method,
double transgenic embryos were recovered by crossing the Tg(T2/
OncZ,ß -actin:RFP) line to the Tg(Tol2,ß-actin:SB11, cmlc2:GFP.)
is8
line that expresses SB11 under the control of the ß-actin promoter
(Fig. 3 B). Embryos were aged to 5 day post fertilization (dpf) and
genomic DNA isolated from the larvae for PCR. In the T2/OncZ
concatemer each transposon has ,200 bp of plasmid vector
sequence flanking the transposon on both sides (Fig. 3 C). Primers
1 and 4 are complementary to these flanking sequences and are
expected to amplify an ,200 bp product only if the transposon
has excised from the concatemer and the excision site is repaired
(Fig. 3 C). The excision PCR product, which indicates T2/OncZ
transposons have excised from the concatemer, is present in
embryos doubly heterozygous for the T2/OncZ concatemer and
Tg(Tol2,ß-actin:SB11, cmlc2:GFP.)
is8 transgenes (Fig. 3 C, aster-
isk), but absent from embryos carrying the concatemer alone. A
similar result was obtained when transposase was supplied by
injection of SB11 mRNA into Tg(T2/OncZ,ß -actin:RFP)
is6 embryos
(Fig. 3 A, C, asterisk). We confirmed that the PCR products
represent the excision footprint by sequencing (data not shown).
These results demonstrate that the T2/OncZ concatemers contain
functional transposons that can be excised from the concatemer.
In addition, the results show that the SB11 transposase expressed
from either an mRNA or a transgene can actively promote
mobilization of transposons out of the concatemer.
Demonstration of genome-wide T2/OncZ transposon
integration after transient or constitutive exposure to
SB11 transposase
To test whether the T2/OncZ system is effective at producing
genome-wide somatic insertional mutations, we examined the extent
of re-integration following injection of SB11 mRNA into 1-cell stage
embryos that had either the Tg(T2/OncZ,ß -actin:RFP)
is6 (,500
copies) or Tg(T2/OncZ,ß -actin:RFP)
is7 (,70 copies) concatemer
(Fig. 3 A, Table 2, Experiments 1 and 2). At one year of age, three
fish(1a,1b,and6)thathaddevelopedlargetumors(describedbelow)
were sacrificed and DNA was isolated separately from muscle tissue
(C, control) and tumor tissue (T, tumor). Junction fragments from
transposon integration sites were amplified using a ligation-mediated
PCR protocol [16] with barcoded primers adapted for next
generation sequencing on the Illumina/Solexa platform (Table 3).
The sequences were trimmed and the transposon–genomic DNA
junction fragments were mapped to the zebrafish v8 RefSeq genome
(http://www.sanger.ac.uk/resources/zebrafish). We recovered 1630,
717, and 2479 unique integration sites in control 1aC, 1bC, and 6C
samples, respectively (Table 4 and Dataset S1), that mapped to TA
dinucleotides in the zebrafish genome. These data indicate that the
short burst of transposase expression from mRNA injection in the
embryo was enough to trigger widespread transposon mobilization
and re-integration.
The T2/OncZ re-integration site data for individual samples was
plotted and revealed that in each sample the integration events
mapped to every chromosome (Fig. 4 A–C, black line plots). The
average number of integration sites per Mb across each
chromosome was ,0.5, 1 (samples 1bC and 1aC), or 2 (sample
6C) and appeared evenly distributed across the genome with two
exceptions. First, in each sample a large number of re-integration
sites mapped to chromosome 3 (Figure 4, A–C, arrows), where the
zebrafish ß-actin gene is located. These are most likely re-
integration events in the ß-actin promoter present in the T2/OncZ
transposon (Dataset S1). Second, in each sample one chromosome
has a higher frequency of re-integration events than the rest
(Figure 4 A–C, asterisks). For example, in Tg(T2/OncZ,ß -
actin:RFP)
is6 sample 1a the peak on chromosome 16 indicates
there are ,1.5 times as many events as on the other chromosomes
(Fig. 4 A asterisk). In Tg(T2/OncZ,ß -actin:RFP)
is7 sample 6C, the
highest frequency of re-integration events mapped to chromosome
5 (Fig. 4 C asterisk). The cluster of integration sites most likely
represents transposon excision and re-integration to locations
linked to the concatemer, a previously reported phenomenon
[10,11] that is discussed further below. Interestingly, in control
tissue from fish 1b the distribution of integration sites was relatively
even across each chromosome, without an obvious peak
representing linkage to the predicted concatemer location on
chromosome 16 (Fig. 4 B). However, analysis of the integration
sites from the tumor tissue isolated from fish 1b shows a peak on
chromosome 10 (Fig. 4 B asterisk). One explanation for this
Figure 2. Isolation of transgenic zebrafish expressing consti-
tutive SB11 transposase. (A) Diagram of miniTol2 vector containing a
constitutive ß-actin promoter: SB11 cDNA cassette. 59 and 39, Tol2
inverted terminal repeats; zf ß-a 39UTR, zebrafish ß-actin 39 UTR; cmlc2,
zebrafish cardiac myosin light chain 2 promoter. (B) Western blot
demonstrates the expression of SB11 in Tg(Tol2,ß-actin:SB11,
cmlc2:GFP.) transgenic embryos. The blot was stripped and re-probed
with an anti-ß-actin antibody for loading control.
doi:10.1371/journal.pone.0018826.g002
Table 1. Transgenic zebrafish lines isolated in this study.
Transgenic line Transgene copy number Notes
Tg(T2/OncZ,ß-actin:RFP)
is7 ,70 copy concatemer RFP reporter integrated into concatemer
Tg(T2/OncZ,ß-actin:RFP)
is6 ,500 copy concatemer RFP reporter integrated into concatemer
Tg(Tol2,ß-actin:SB11, cmlc2:GFP.)
is8 single Tol2 transposon with SB11 transposase cassette contains heart-specific GFP reporter cassette
Tg(Tol2,ß-actin:SB11, cmlc2:GFP.)
is9 single Tol2 transposon with SB11 transposase cassette contains heart-specific GFP reporter cassette
doi:10.1371/journal.pone.0018826.t001
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part of the concatemer occurred in the developing embryo after
injection of SB11 transposase mRNA. Subsequently, the cells that
inherited the rearrangement went on to contribute to the tumor in
the adult. This is a reasonable explanation, given that transposi-
tion from a concatemer has been previously shown in mice to
cause genomic rearrangements at the concatemer chromosomal
site [41].
The experiments described above demonstrated that supplying
a transient source of SB11 transposase by injection of mRNA into
Figure 3. Two strategies for T2/OncZ insertional mutagenesis in zebrafish somatic tissues. (A) Methods 1: Injection of in vitro transcribed
SB11 mRNA at the 1-cell stage. (B) Method 2: Genetic cross between Tg(T2/OncZ,ß -actin:RFP)( T2/OncZ) and constitutive Tg(Tol2,ß-actin:SB11,
cmlc2:GFP.)( ß -actin:SB11) fish. At 24 hpf embryos are sorted into 4 progeny classes. (C) Excision PCR assay on 5 dpf larvae to demonstrate
mobilization of transposons out of the concatemer in the presence of SB11 transposase. Primers 1 and 4 amplify a 220 bp band (red asterisk) flanking
the transposon excision site in the concatemer. Left panel, Tg(T2/OncZ,ß -actin:RFP)
is6 larvae; middle panel, SB11 injected Tg(T2/OncZ,ß -actin:RFP)
is6
larvae; right panel, double transgenic Tg(T2/OncZ,ß -actin:RFP)
is6; Tg(Tol2,ß-actin:SB11, cmlc2:GFP.) larvae.
doi:10.1371/journal.pone.0018826.g003
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compared the extent of transposon mobilization after transient
transposase expression with the constitutive SB11 transgene. To
do this we cloned and analyzed the distribution of transposon
integration sites in the genomes of four three-month-old fish that
were doubly transgenic for the Tg(T2/OncZ,ß -actin:RFP)
is6
concatemer and the Tg(Tol2,ß-actin:SB11, cmlc2:GFP.)
is8 trans-
gene (Figure 3 B, Table 4 Experiment 3). Between 4446–6842
unique integration sites were identified per tissue sample (Table 4
and Dataset S1). The average number of integration sites per Mb
was between 2 and 6 in samples 1C, 2C, 3C and 5C (Fig. 4 D), at
least twice the number seen after supplying SB11 transposase
transiently in the embryo (Fig. 4 A–C). This could reflect the
continued transposition driven by the constitutive transposase
through adult stages.
In each of the four Tg(T2/OncZ,ß -actin:RFP)
is6; Tg(Tol2,ß-
actin:SB11, cmlc2:GFP.)
is8 samples a peak of integration was
observed on chromosome 16 (Fig. 4 D). This was consistent with
what was observed in SB11 injected fish 1a (Fig. 4 A) and provides
additional support for the location of Tg(T2/OncZ,ß -actin:RFP)
is6
on chromosome 16. Assuming that transposons should re-integrate
randomly across the genome, we calculated the expected
frequency of integration events for each chromosome based on
what proportion of the genome each chromosome represents in
Mb. Chi-square tests of the observed and expected frequencies of
integration events in a double transgenic Tg(T2/OncZ,ß -
actin:RFP)
is6 ; Tg(Tol2,ß-actin:SB11, cmlc2:GFP.)
is8fish (sample
5C) indicate the distribution of transposon integrations sites was
significantly different than expected (two tailed P,0.0001).
Although the expected number of integration events is an
approximation based on size and not the distribution of TA
dinucleotides on each chromosome, the data are consistent with
linkage of the Tg(T2/OncZ,ß -actin:RFP)
is6 concatemer to chromo-
some 16. Similarly, chi-square tests of integration sites in the ,70
copy number concatemer sample Tg(T2/OncZ,ß -actin:RFP)
is7 6C
(Fig. 4 C) indicated a significant difference in the distribution
compared to the expected (two tailed P,0.0001). The analysis
provides additional evidence that the Tg(T2/OncZ,ß -actin:RFP)
is7
concatemer is linked to chromosome 5.
Within each sample from double transgenic ß-actin:SB11
is8 ; T2/
OncZ
is6 fish the number of integration events that are in or near a
gene ranged from 3567–5469, or 80–82% of the total integration
Table 2. Somatic mutagenesis experiments performed in this study.
Mutant Class Control Siblings
Experi-
ment
Parental
Genotype
Parental
Genotype
Transposase
Source Genotype
Tumor
Incidence
tp53
M214K
Genotype Genotype
Tumor
Incidence
tp53
M214K
Genotype
1 Tg(T2/OncZ)
is6/+ Tg(T2/OncZ)
is6/+ SB11 mRNA
injection
T2/OncZ/+ 3/29* NA +/+ 0/20 NA
2 Tg(T2/OncZ)
is7/+ ;
tp53/+
+/+ ; tp53/tp53 SB11 mRNA
injection
T2/OncZ/+ 1/48
# tp53/++ /+ 0/55 NA
3 Tg(T2/OncZ)
is6/+ Tg(ß-a:SB11)
is8/+ constitutive
transgene
T2/OncZ/+ ;
ß-a:SB11/+
0/40 NA T2/OncZ/+ ;
+/+
0/41 NA
4 Tg(T2/OncZ)
is6/+ ;
tp53/+
Tg(ß-a:SB11)
is8/+ ;
+/+
constitutive
transgene
T2/OncZ/+ ;
ß-a:SB11/+
2/3‘ tp53/+ T2/OncZ/+ ;
+/+
0/18 NA
Tumor incidence measured at 1–1.5 years.
tp53
M214K allele previously described in Berghmans et al., 2005.
*Tumor 1aT, intestinal mass, pathology not determined; tumor 1bT, spindle cell sarcoma; tumor 1cT, abdominal mass, pathology not determined.
#Tumor 6T, carcinoma.
‘Tumor 2T, mixed spindle cell and histiocytic sarcoma; tumor 8T, spindle cell sarcoma.
doi:10.1371/journal.pone.0018826.t002
Table 3. 59-39 Sequence of barcoded oligos for ligation-mediated PCR of T2/OncZ transposon-genomic DNA junction fragments.
Primer Illumina Adaptor Sequence Barcode T2 transposon arm sequence
BC1 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT AGGAGT TGTATGTAAACTTCCGACTTCAACTG
BC2 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT GCGAGT TGTATGTAAACTTCCGACTTCAACTG
BC3 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT CTGAGT TGTATGTAAACTTCCGACTTCAACTG
BC4 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT AACAGT TGTATGTAAACTTCCGACTTCAACTG
BC5 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT GGCAGT TGTATGTAAACTTCCGACTTCAACTG
BC6 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT TCCAGT TGTATGTAAACTTCCGACTTCAACTG
BC7 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT GATAGT TGTATGTAAACTTCCGACTTCAACTG
BC8 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT CGTAGT TGTATGTAAACTTCCGACTTCAACTG
BC9 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT ACTAGT TGTATGTAAACTTCCGACTTCAACTG
BC10 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT GAAGGT TGTATGTAAACTTCCGACTTCAACTG
BC11 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT AGAGGT TGTATGTAAACTTCCGACTTCAACTG
BC12 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT CCAGGT TGTATGTAAACTTCCGACTTCAACTG
doi:10.1371/journal.pone.0018826.t003
SB Transposon Somatic Mutagenesis in Zebrafish
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revealed that in each double transgenic sample 22–28% of the
genes have multiple independent insertion sites (Table 4). The
number of independent integrations in a gene ranged from 1 to
.4 in each sample, with 22, 32, 56 and 102 genes in the different
samples having 4 or more independent integration events (Table 4,
samples 5C, 1C, 2C, 3C). Surprisingly, multiple independent
insertions were also detected in 11–16% of the genes after
transient expression of transposase by SB11 mRNA injection into
the embryo (Table 4). Multiple independent events in a gene in
one tissue sample could represent intragenic excision and re-
integration, as described previously in mouse [10,11,17,18]. The
ability to detect these multiple events may result from the massive
sequencing capability of the Illumina/Solexa platform, compared
with previous high throughput methods. In summary, both
methods we tested for introducing transposase into the T2/OncZ
concatemer lines resulted in transposition and genome-wide re-
integration.
T2/OncZ mutagenesis leads to tumor induction after
transient or constitutive exposure to SB11 transposase
To determine if transposon re-integration in the zebrafish T2/
OncZ system would lead to tumorigenesis, we monitored the Tg(T2/
OncZ,ß -actin:RFP)
is6 zebrafish exposed to transient or constitutive
transposasefor gross evidenceofneoplasmsor tumors. In a wildtype
background, 10% (3/29) of the .500-copy number concatemer
Tg(T2/OncZ,ß -actin:RFP)
is6 adults that had been injected with SB11
mRNAat the1-cell stage developed grosstumorsbeginning at about
1 year of age (Table 2, Experiment 1). Twenty control siblings that
were injected and reared alongside the Tg(T2/OncZ,ß -actin:RFP)
is6
positive fish showed no evidence of neoplasms. Naturally occurring
neoplasms have been reported in zebrafish with varying frequencies
[42,43,44], however, we have not observed spontaneous tumors in
the T2/OncZ transgenic lines or in the wild type populations of fish
raised in our facility. We harvested the tumor from one of the
mutagenized fish (1a) and performed both histopathology and
transposon re-integration site analysis. In fish 1a a mesenchymal
neoplasm was located in the abdominal body wall (Fig. 5 A). The
neoplasm consisted of densely packed and highly cellular cords of
spindle shaped cells within a fine fibrous stroma; a microscopic
appearanceconsistentwithspindlecellsarcoma(Fig.5E).Neoplastic
cells invaded extensivelyintoand separated the skeletal muscleof the
abdominal wall. Together, these results indicate that SB transposon
mutagenesis induces tumors in zebrafish adults.
We examined whether predisposing fish to cancer in a tumor
suppressor mutant background would accelerate tumor onset and
increase the frequency of tumors after T2/OncZ mutagenesis.
Homozygous tp53
M214K mutant zebrafish are susceptible to
development of peripheral nerve sheath tumors [31]. SB11 mRNA
was injected into embryos from a cross between the 70 copy
Figure 4. Re-integration of T2/OncZ after transient or constitutive SB11 transposase expression. (A, B, C) The average number of re-
integration sites per Mb plotted across all 25 chromosomes for tumor (T) and control (C) muscle samples from fish #1a, #1b and #6. Transposase
source was supplied as SB11 mRNA injected at the 1-cell stage into Tg(T2/OncZ,ß -actin:RFP)
is6 (fish #1a, #1b) or Tg(T2/OncZ,ß -actin:RFP)
is7 (fish #6)
embryos. (D) The average number of re-integration sites per Mb plotted across all 25 chromosomes for control samples from fish 1C, 2C, 3C, and 5C,
and tumor samples from fish 2T and 8T. Fish were double heterozygous Tg(T2/OncZ,ß -actin:RFP)
is6 ;Tg(Tol2,ß-actin:SB11, cmlc2:GFP.).
doi:10.1371/journal.pone.0018826.g004
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is7 concatemer line and homo-
zygous tp53
M214K zebrafish, so that all progeny were heterozygous
for the tp53
M214K allele (Table 2, Experiment 2). Transgenic and
non-transgenic progeny were monitored for evidence of neoplasms
(Table 2). At 9 months of age, one adult zebrafish (1/48–2%) that
was injected with SB11 mRNA developed a large neoplasm rostral
and ventral to the pectoral fin (Fig. 5 C). None of the 55 non-
transgenic siblings developed tumors. The neoplasm in the fish
was composed of densely packed nests of cuboidal to polygonal
cells that had moderate anisocytosis and anisokaryosis. In multiple
foci neoplastic cells were arranged into tubular/acinar structures
(Fig. 5 G). The morphology of neoplastic cells suggests an epithelial
origin, indicating a carcinoma, which is different from the typical
MPNSTs that arise due to p53 heterozygosity. The tp53 genotype
of DNA isolated from the tumor and control muscle tissue of the
fish was determined by amplification and sequencing of a 200 bp
fragment surrounding the M214K lesion. The results indicate that
the control muscle tissue and tumor tissue were heterozygous for
the tp53
M214K allele (data not shown). It is possible that DNA from
stromal tissue in the tumor contributed to the presence of the wild
type allele in the genotyping data. However, given the absence of
tumor induction in 55 non-transgenic control siblings, it is less
likely that the tumor appeared after spontaneous loss of the wild
type tp53
M214K allele. The lower frequency of tumor induction
observed in these experiments (2%), compared to the frequency
for the high copy number concatemer (10%), suggests transposon
copy number positively correlates with tumor induction frequency.
Predisposing fish with a single copy of mutant tp53 likely did not
compensate for the lower transposon dosage in the lower copy
number concatemer line.
The introduction of transposase by mRNA injection was able to
induce tumors in wild type and p53 heterozygous adult T2/OncZ
fish, albeit at a low frequency. We expected that a continuous,
transgenic source of SB11 transposase would result in an increase
in tumor frequency and a decrease in latency, particularly in the
predisposed p53 background. However, zero out of 40 double
transgenic T2/OncZ
is6 ;ß -actin:SB11
is8 adults developed tumors by
1 year of age (Table 2, Experiment 3). Additionally, in crosses
between the constitutive ß-actin:SB11 transposase and the ,500
copy number T2/OncZ concatemer line that was heterozygous for
the tp53
M214K allele, only three out of approximately 20 double
transgenic progeny survived (Table 2, Experiment 4). However, at
1.5 years two of the three adults developed gross neoplasms (Fig. 5
B, D), while 0/18 siblings that did not inherit the ß-actin:SB11
transgene showed signs of tumors (Table 2, Experiment 4). These
data are consistent with the idea that mutant p53 predisposes fish
to increased tumorigenesis and further supports the observation
that transposon dosage in the concatemer correlates with tumor
incidence. In fish 2 we identified a neoplasm in the dorsal cervical
region (Fig. 5 B). This neoplasm appeared to be composed of two
neoplastic cell populations each with distinct morphology. The
first cell type was characterized by loosely packed sheets of round
cells within a fine fibrous stroma (Fig. 5 F). The second neoplastic
population consisted of densely packed and highly cellular spindle
shaped cells within a fibrous stroma (Fig. 5 F). Neoplastic cells in
both populations had had moderate anisocytosis and anisokar-
yosis. Our interpretation of these findings was that this was a
mixed neoplasm containing two neoplastic cell phenotypes,
mesenchymal and round cell. These morphologies are consistent
with spindle cell sarcoma and histiocytic sarcoma, respectively. In
fish 8 there was a mesenchymal neoplasm located in the
abdominal cavity with abundant fibrous tissue that may indicate
further differentiation and classification as fibrosarcoma. Neoplas-
tic cells had moderate anisocytosis and anisokaryosis (Fig. 5 H).
The morphology of this neoplasm is consistent with spindle cell
sarcoma. We determined the tp53 genotype of control muscle
tissue and tumor tissue from both fish 2 and fish 8 using PCR and
sequencing. Like control tissue, the tumor DNA remained
heterozygous for the tp53
M214K allele. These results are consistent
with T2/OncZ mutagenesis driving tumorigenesis in these
neoplasms, as opposed to loss of heterozygocity at the tp53 locus.
T2/OncZ transposon integration site analysis in neoplastic
tissue
We examined the profile of transposon sites from neoplastic
tissues (Table 4, Dataset S1) and compared the gene insertion list
with human and mouse cancer genome databases. We isolated
Figure 5. Histopathologic features of solid tumors in T2/OncZ mutagenized fish. (A–D) gross images of neoplasms in fish 1a, 2, 6, and 8
respectively. (E–H) Histopathology of zebrafish neoplasms: Hematoxylin and Eosin stained sections at 10006magnification. (E) Spindle cell sarcoma
from fish 1a, note entrapped skeletal muscle fibers (arrow). (F) Mixed neoplasm from fish 2, neoplastic round cells (arrow) were intermixed with
neoplastic spindle shaped cells (arrow head). (G) Carcinoma from fish 6, neoplastic cells were arranged into multiple acinar structures (arrow). (H)
Spindle cell sarcoma from fish 8, note the mitotic figure (arrow). Scale bar A–D, 0.5 cm; E–H, 50 um.
doi:10.1371/journal.pone.0018826.g005
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integration sites for every tumor and control tissue is provided in
Dataset S1. The integration site list was filtered according to a
method previously used in the analysis of T2/Onc integration sites
from mouse [16]. This analysis is designed to create a conservative
estimate of the genes that contribute to cellular transformation
based on their representation in the Illumina sequence data set.
Using this method we identified in each tissue sample the
integration sites two standard deviations above the mean, which
potentially represent transposon integrations that were clonally
expanded during tumor growth (Table 5, Dataset S2). The
number of annotated genes for all zebrafish tumor samples (T)
after filtering is 149. Interestingly, insertions at different locations
in the GALNTL6 gene that encodes N-acetylgalactosaminyltrans-
ferase-like 6 were observed in two tumor samples, 2T and 8T.
We then compared the gene list from the zebrafish tumors with
the mouse retroviral tagged cancer gene database (RTCGD:
retroviral tagged cancer gene database, http://RTCGD.ncifcrf.
gov) [45]. Retroviral insertions were present in the mouse
homologs of 10 genes tagged in the zebrafish tumor samples:
Brd2, Cirbp, Fgf8, Hexim1, Map2k5, Mmp14, Ncoa2, Slc30a5, Sox4,
and Sox5 (Table 6). Additionally, a T2/OncZ transposon insertion
in Snapc3 was observed in tumor 8T, a gene previously identified
with a T2/Onc insertion in mouse tumor samples [11]. We also
compared the zebrafish tumor integration gene list with the
Cancer Genome Project Cancer Gene Census (http://www.
sanger.ac.uk/genetics/CGP/Census/) [46]. This revealed that
eleven of the zebrafish genes (11/149; 7.4%) have human
homologs that are causally implicated in various cancers
(Table 6): CBFB, CBL, EXT1, GATA2, MSI2, NCOA2, NCOA4,
PBX1, PRDX5, SMARCB1, and TSHR (Table 6). We performed
the same analyses using the integration data from all control
samples. Twelve of the 602 genes (2%) from the control samples
were represented in the Cancer Gene Census list (BRD3, CBFB,
CRLF2, ETV1, GPHN, FANCG, JAZF1, KTN1, MAF, NFKB2,
NRAS, SFPQ), and nineteen (3.2%) were present in the mouse
RTCGD database (Cnr2, Dlst, Fancg, Ghr, Igf1r, Inadl, Jazf1,
Map2K5, Nfkb2, Nras, Nrxn2, Ppap2b, Ppp1r14b, Prlr, Rras2, Rtn4ipl,
Tmem86a, Vac14, Zdhhc18). The observed frequencies of integra-
tion into known cancer genes are significantly higher in the tumor
samples than expected by chance (chi-square test P,0.002 and
P,0.02 when comparing representation in Cancer Census List
and RTCGD, respectively). Together, the results indicate the
zebrafish tumors induced by T2/OncZ mutagenesis have an
increased frequency of mutations in the homolog of known human
and mouse cancer genes. This analysis validates our mutagenesis
approach and provides additional comparative support for the
involvement of these genes in human cancer.
Discussion
The SB T2/OncZ system presented in this study provides a
robust strategy for insertional mutagenesis in somatic tissues in
zebrafish. The results demonstrate that transient or constitutive
sources of SB11 transposase effectively mobilize transposition from
a stable T2/OncZ concatemer followed by genome-wide re-
integration. T2/OncZ re-integration was randomly distributed
across the genome and evenly distributed along each chromosome.
The exceptions were a high number of re-integration events on
chromosome 16 in concatemer line Tg(T2/OncZ,ß -actin:RFP)
is6,
and on chromosome 5 in line Tg(T2/OncZ,ß -actin:RFP)
is7, which
indicates linkage of the concatemer to these chromosomes.
The somatic mutagenesis strategy described here results in
highly mosaic tissues with respect to transposon integration sites.
In each sample there was at least 1 integration event per Mb on
each chromosome, and in some samples the number was as high
as 6. Variation in the average number of integrations could
represent differences in the density of genes along each
chromosome, since the plotted data represents integration sites
that map to unique locations in the genome. Remarkably, we were
able to detect multiple independent integration events in 21–28%
of tagged genes from control fish when the constitutive ß-
Table 5. Number of T2/OncZ re-integration sites/sample after filtering.
Sample # of sites
# of mapped
reads Avg. read #
standard
deviation Cut off value
# of sites above
Cut off value
# annotated
genes
1aC 1621 51475 31 388 806 10 7
1bC 693 43805 62 347 758 14 10
6C 2452 182394 74 526 1126 51 45
1aT 2578 239283 93 1061 2215 34 26
1bT 1826 194852 107 2027 4160 5 4
6T 1811 74780 41 529 1099 11 9
1C 4220 345805 78 305 688 155 127
2C 5353 520800 97 316 730 238 193
3C 6834 718548 105 359 824 247 185
5C 4461 215711 48 345 738 70 47
2T 2304 205197 89 355 800 90 72
8T 2308 228567 99 571 1243 55 49
Samples 1aC, 1bC, and 6C are from normal muscle tissue from fish 1a, 1b, 6.
Samples 1aT, 1bT, and 6T are from tumor tissue from fish 1a, 1b, 6.
Samples 1C, 2C, 3C, and 5C are from ß-actin:SB11;T2/OncZ
is6 double transgenic control fish.
Samples 2T and 8T are from tumor tissues from ß-actin:SB11;T2/OncZ
is6 double transgenic fish.
Reads that mapped to the ß-actin promoter were removed from each sample before calculating values.
Cut off value is equal to two standard deviation units above the average read # in that sample.
# annotated genes is the # of sites within an annotated gene or positioned 59 or 39 to an annotated gene.
doi:10.1371/journal.pone.0018826.t005
SB Transposon Somatic Mutagenesis in Zebrafish
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18826actin:SB11 transgene was used as the transposase source. Multiple
integration sites within a gene were also detected in 11–16% of
tagged genes in DNA samples from fish that were injected with
SB11 mRNA. Intragenic excision and re-integration has previ-
ously been reported in mouse T2/Onc tumors [10,11,17,18] and
was interpreted to represent the selection of integrations that
create mutations favorable for tumor cell survival and mainte-
nance. The data presented here suggest that similar events occur
with the zebrafish T2/OncZ system, not only in tumor tissues, but
in control tissues as well. The ß-actin:SB11 transgene appears to
provide a constant level of transposase. This is evident in the
absence of a large number of re-integration events surrounding the
concatemer linkage site on chromosome 16 in tumors from double
transgenic Tg(ß-actin:SB11)
is8; Tg(T2/OncZ,ß -actin:RFP)
is6 fish aged
1–1.5 years and the increased frequency of multiple transposon
insertions in single genes. The data are consistent with continuous
mobilization and dispersal of T2/OncZ transposons across the
genome as the fish age.
Given the robust transposition and transposon re-integration we
observed in somatic tissues, the transgenic T2/OncZ system could
be an effective tool for germline mutagenesis screens. SB was first
shown to promote germline transposition and transgenesis in mice
[47,48] and was further developed as a germline mutagenesis tool
[47,49]. In zebrafish SB has been used for transgenesis and
germline mutagenesis screens by injection of transposase RNA and
transposon DNA into the embryo [50,51,52,53]. Similar strategies
for SB-mediated transgenesis in the germline have also been
demonstrated in medaka [54] and Xenopus [55]. We show in the
current study that the T2/OncZ system promotes a high level of
transposition and genome-wide integration. Germline mutagenesis
in the mouse starting with transgene concatemers has previously
been shown for both the T2/Onc transposon [41] and a gene trap
T2 vector [56]. Adopting the T2/OncZ system for germline
mutagenesis might increase the efficiency of insertional mutagen-
esis screens compared to previous transgenic methods in zebrafish
[57].
Introducing a transient source of transposase into the high copy
number T2/OncZ concatemer line by RNA injection resulted in a
tumor frequency of 10%. The occurrence of tumors was
surprising, given that transposase expression is transient and the
embryo is mosaic for integration sites in individual cells. Although
2 out 3 double transgenic Tg(ß-actin:SB11)
is8; Tg(T2/OncZ,ß -
actin:RFP)
is6 developed tumors, the small number of fish that
survived to adulthood prevents an estimate of the true frequency of
tumor induction using constitutive transposase. We are currently
testing an alternative Tg(ß-actin:SB11) line to optimize SB11
Table 6. Comparison of zebrafish and human and mouse cancer genes.
Zebrafish Gene* Human Gene
# COSMIC Cancer Gene Census
% Mouse RTCGD Cancer Gene‘
brd2b BRD2 -X
cbfb CBFB X-
cbl CBL X-
cirbp CIRBP -X
ext1c EXT1 X-
fgf8a FGF8 -X
gata2a GATA2 X-
zgc:162976 HEXIM1 -X
zgc:172137 MAP2K5 -X
mmp14b MMP14 -X
msi2b MSI2 X-
ncoa2 NCOA2 XX
zgc:55307 NCOA4 X-
pbx1a PBX1
$ X-
prdx5 PRDX5 X-
slc30a5 SLC30A5 -X
smarcb1b SMARCB1 X-
snapc3 SNAPC3 -X
si:dkey-76p14.4 SOX4 -X
sox5 SOX5 -X
LOC560609 TSHR X-
*Zebrafish genes with T2/OncZ insertion in tumor tissue in the present study.
#Human Gene: BRD2, bromodomain containing 2; CBFB, core-binding factor, beta subunit, CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence; EXT1,
exostosin 1; FGF8, fibroblast growth factor 8 (androgen-induced); GATA2, GATA binding protein 2; HEXIM1, hexamethylene bis-acetamide inducible 1; MAP2K5,
mitogen-activated protein kinase kinase 5; MMP14, matrix metallopeptidase 14 (membrane-inserted); MSI2, musashi homolog 2 (Drosophila); NCOA2, nuclear receptor
coactivator 2; NCOA4, nuclear receptor coactivator 4; PBX1, pre-B-cell leukemia homeobox 1; PRDX5, peroxiredoxin 5; SLC30A5, solute carrier family 30 (zinc
transporter), member 5; SMARCB1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1; SNAPC3, small nuclear RNA
activating complex, polypeptide 3, 50 kDa; SOX4, SRY (sex determining region Y)-box 4; SOX5, SRY (sex determining region Y)-box 5; TSHR, thyroid stimulating
hormone receptor.
%Gene identified as a human Cancer Gene in the Cancer Gene Census List.
‘Gene identified as a CIS in mouse tumor tissues by retroviral or T2/Onc transposon insertion. X, present in Human Cancer Gene Census or mouse RTCGD: -, absent.
$PBX1 is mutated by translocation in human pre B-ALL, myoepithelioma.
doi:10.1371/journal.pone.0018826.t006
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backgrounds, in order to increase the frequency of tumor
induction.
This study demonstrates the capability of the Sleeping Beauty T2/
OncZ system for genome-wide insertional mutagenesis in somatic
tissues in zebrafish and the potential for identifying novel cancer
genes. The comparison of T2/OncZ integration sites in the five
zebrafish tumors to the human Cancer Gene Census and mouse
Retroviral and Transposon Cancer Genome Database revealed
overlapping genes. Three of the five tumors had a T2/OncZ
insertion in one gene (CBL, TSHR,o rSMARCB1) known to be
highly mutated in human cancers [46]. While these insertions
could be interpreted as the activating mutations responsible for
initiating cellular transformation and tumor progression, similar
insertions from multiple tumors are necessary to support that
conclusion. This comparative approach among zebrafish, mouse
and human provides additional evidence in support of putative
cancer genes and the conservation of genetic pathways mutated in
cancer.
Future studies examining integration events in large numbers of
zebrafish tumors will be necessary to identify novel cancer genes as
has been done previously in mouse SB-induced cancer models
[10,11,17,18]. Modification of the system using alternative T2/
OncZ vectors, or combining transposase injection and transgenic
sources, could increase tumor frequency. However, the ability to
scale up the mutagenesis strategy in order to recover significant
numbers of tumor samples is straightforward using zebrafish. For a
standard zebrafish laboratory it is feasible to inject 500 embryos,
or recover 500 double transgenic fish, and raise the fish to
adulthood. One important future use of the T2/OncZ system is to
combine it with other zebrafish models of human cancers to screen
for enhancers of tumor onset, progression and possibly metastasis.
These studies will provide a novel strategy for elucidating the
genetics pathways that drive cellular transformation and tumor-
igenesis in human cancer.
Methods
Ethical Statement
Animals were reared and euthanized according to protocol
#06-D-029-A approved by the Iowa State University IACUC
Committee. All efforts were made to minimize suffering.
Zebrafish strains
Zebrafish were reared and housed in an AHAB system (Aquatic
Ecosystems, Inc.) and kept under a 14 hour light/10 hour dark
photoperiod at 27uC. Wild type zebrafish were obtained from 5-D
Tropical Inc. (Florida). WIK, TU, and the tp53
M214K lines were
obtained from the Zebrafish International Research Center
(ZIRC).
Isolation of transgenic Tg(T2/OncZ, ß-actin:RFP)
concatemer lines
The SB T2/OncZ transposon was built by modifying the
previously characterized T2/Onc vector [10] by inserting the carp
ß-actin promoter [33] (detailed cloning steps are provided in
Methods S1. To isolate zebrafish lines carrying T2/OncZ
concatemer arrays linear DNA fragments containing T2/OncZ
and the ß-actin:RFP reporter cassette were co-injected into
embryos. The pT2/OncZ vector was digested PvuI and BsaXIt o
release a ,4.9 Kb fragment containing the transposon flanked by
160 bp and 280 bp of vector sequence at the 59 and 39 ends,
respectively. The 4.9 Kb T2/OncZ fragment was mixed at a 2:1
ratio with a 3.1 Kb fragment containing a ß-actin:RFP reporter
cassette to a final concentration of 250 pg/nl. The DNA was
diluted 16 in Danio buffer and 125–250 pg injected into 1-cell
WIK or wild type embryos. Founders were raised to adulthood
and screened by outcrossing with WIK or wild type and
examining F1 embryos for ubiquitous RFP expression at 24 hpf.
Out of 54 founders screened, seven independent F1 concatemer
lines were recovered. Tg(T2/oncZ,ß -actin:RFP)
is6 (.500 copy
number) and Tg(T2/OncZ,ß -actin:RFP)
is7 (75 copy number) were
kept and the remaining 5 lines were not maintained.
Genomic Southern blotting, Western blotting, transposon
excision PCR assay, and isolation of transposase mRNA are
described in Methods S1.
Isolation of SB11 transposase transgenic lines by Tol2-
mediated transgenesis
Details of the molecular construction of Tol2,ß-actin:SB11,
cmlc2:GFP. are provided in Methods S1. To isolate SB11
transposase expressing transgenic fish, 50 pg Tol2 mRNA and
100 pg Tol2,ß-actin:SB11, cmlc2:GFP. plasmid was coinjected
into the 1-cell stage WIK embryos. At 24 hpf injected embryos
were screened for mosaic GFP expression in the heart and positive
embryos were selected and raised to adulthood. Adult founders
were outcrossed with wild type and the F1 embryos screened for
GFP expression in the heart. Nine independent F1 Tg(Tol2,ß-
actin:SB11, cmlc2:GFP.) lines were recovered after screening 22 F0
founder adults. Lines Tg(Tol2,ß-actin:SB11, cmlc2:GFP.)
is8 and
Tg(Tol2,ß-actin:SB11, cmlc2:GFP.)
is9 were maintained.
Somatic Mutagenesis Strategies
Heterozygous transgenic Tg(T2/OncZ,ß -actin:RFP) adult males
were crossed to heterozygous Tg(Tol2,ß-actin:SB11, cmlc2:GFP.)
females. Embryos were collected and aged to 24 hpf or 48 hpf and
sorted into 4 progeny classes based on ubiquitous RFP expression
and heart-specific GFP expression. Approximately, 50 individuals
in each progeny classes were reared in separate tanks and
examined for macroscopic tumors before sacrificing and harvest-
ing tissues for DNA isolation and pathology. For transposase
mRNA injections, Tg(T2/OncZ,ß -actin:RFP) males were out-
crossed to WIK females and ,50 pg of SB11 mRNA injected into
1-cell stage embryos. At 24 hpf embryos were separated into
RFP+ and RFP- classes and reared in separate tanks.
Histopathology
Tissue and tumors were dissected from anesthetized adults and
fixed in 10% buffered Formalin (Fisher). All tissues were
embedded in paraffin and processed for routine sectioning
(4 um) and hematoxylin and eosin staining (H&E) at the
Histopathology Laboratory, Department of Veterinary Pathology,
in the College of Veterinary Medicine at Iowa State University.
Identification of transposon integration sites
Sequences flanking transposon integration sites were PCR
amplified using a previously described adapter ligation-mediated
PCR protocol [16] that was modified for use with the Illumina/
Solexa Genome Analyzer II. Bar-coded primers used for
amplification are listed in Table 3 and additional methods are
found in Methods S1.
Computational Analyses
Illumina sequences were trimmed to remove primer and
transposon sequences and mapped to the zebrafish genome
assembly v8 using BLAT. Graphical plots of transposon
distribution and density across the genome were created using
SB Transposon Somatic Mutagenesis in Zebrafish
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ku.edu/,preacher/chisq/chisq.htm [58] and http://www.graphpad.
com/quickcalcs/chisquared1.cfm?Format=C.
Comparative Genomic and Network Analyses
Filtered datasets of integration sites were analyzed for cross-
contamination between samples processed on the same day and
sequenced in the same Illumina run. The identical location for 6
integration sites in the tumor samples was also present in one or
more control samples. The corresponding genes were removed
from the tagged gene list before performing comparative genomic
analyses.
Supporting Information
Dataset S1 Tabs are provided for all T2/OncZ integra-
tion sites from SB11 mRNA injected tumor and control
zebrafish (all sites SB11 injected), and all T2/OncZ
integration sites from tumor and control zebrafish with
Tg(Tol2,ß-actin:SB11, cmlc2:GFP.) (all sites BaSB11
transgene).
(XLS)
Dataset S2 Tabs are provided for all T2/OncZ integra-
tion sites remaining in control samples and tumor
samples after filtering the lists to remove sites that fall
below two standard deviations above the mean.
(XLS)
Methods S1
(DOC)
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